Condition: Advanced Tumors · Sponsor: The University of Hong Kong-Shenzhen Hospital
In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy
This description comes directly from the study's public registry record.
Feng-Ming (Spring) Kong · 18807550703 · Kong001@hku.hk
Yan Zhang · 18807550703 · Kong001@hku.hk
Always discuss trial participation with your own doctor first.
| University of Hong Kong-Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
| University of Hong Kong-Shenzhen Hospital | Shenzhen, guangzhou, China | Enrolling By Invitation |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06314087